This is a mechanism module, not a specific disease. Disorder entries reference individual nodes via conforms_to (e.g., "norrin_fzd4_retinal_vascular_development#Insufficient Norrin-FZD4-beta-catenin Signalling in Retinal Endothelium"). Gene substitutions a conforming trigger node makes: NDP (the ligand; X-linked, giving Norrie disease at the severe end and X-linked FEVR at the mild end), FZD4 (the receptor), LRP5 (the co-receptor), TSPAN12 (the potentiator), and ZNF408 and KIF11 in FEVR pedigrees where the link to the pathway is less direct.
Two things a conformer should carry from the module rather than re-derive. First, the severity continuum is a dose effect on one pathway: an entry covering both Norrie disease and X-linked FEVR should model them as points on this chain rather than as separate mechanisms. Second, LRP5 is not retina-specific - the same co-receptor carries canonical Wnt signalling in bone, so LRP5-mutant patients additionally get osteopenia and osteoporosis, and molecularly unsolved FEVR patients warrant bone densitometry. That is a pleiotropy of the gene, not of the retinal mechanism, and belongs on the disorder entry.
SCOPE. This module covers the developmental and barrier-maintenance failure driven by the Norrin system. It is deliberately not a module for retinal neovascularization in general: retinopathy of prematurity and proliferative diabetic retinopathy reach an ischaemic, neovascular retina through hyperoxia-then-hypoxia and through metabolic injury respectively, and share only the downstream VEGF response, which is modelled by tumor_angiogenesis and diabetic_vascular_complications. A conformer here must have a lesion in the Norrin-FZD4 system itself. Note also that Norrin is partially redundant with the Wnt7a/Wnt7b system for blood-brain and blood-retina barrier maintenance, which is why the barrier arm of this module is less severe than the angiogenic arm.
Does residual Norrin-FZD4-beta-catenin signalling amplitude quantitatively predict where a patient falls on the continuum from asymptomatic peripheral avascularity to congenital retinal dysplasia?
KNOWLEDGE GAP
norrin_fzd4_residual_signal_versus_phenotype
Attached to:
Insufficient Norrin-FZD4-beta-catenin Signalling in Retinal Endothelium
This module asserts that the phenotypic continuum is a dose series on one pathway, and the observation that TSPAN12 is a less potent modulator than Norrin itself is consistent with that. But expressivity in these diseases is notoriously variable and asymmetric between the two eyes of one patient, who necessarily share a genotype and therefore share whatever residual signal amplitude the allele permits. Either amplitude is not the whole story, or it varies locally within the developing retina in a way a germline genotype cannot capture. Resolving this determines whether a signalling assay could ever serve as a prognostic test, and whether pathway agonism has a plausible therapeutic window in the inherited disorders as opposed to the acquired ones.
Proposed experiments:
Allele-resolved signalling amplitude against angiographic avascular zone extent
Norrin Ligand, Receptor or Co-receptor Defect
trigger
The initiating lesion is a loss-of-function variant in a component of the Norrin signalling complex: the ligand Norrin (NDP), the receptor Frizzled-4 (FZD4), the co-receptor LRP5, or the potentiator TSPAN12. The genes are functionally non-equivalent in the amplitude of signal they carry - TSPAN12 enhances the Norrin signal rather than transducing it, and is correspondingly less potent - which is part of why the same pathway produces a phenotypic continuum rather than a single phenotype. Inheritance follows the gene: X-linked for NDP, dominant or recessive for FZD4, LRP5 and TSPAN12.
Downstream
-
Insufficient Norrin-FZD4-beta-catenin Signalling in Retinal Endothelium
Insufficient Norrin-FZD4-beta-catenin Signalling in Retinal Endothelium
central effector
The rate-limiting, disorder-agnostic node and the module's key conformance target. Norrin binding to Frizzled-4 with LRP5 and TSPAN12 activates canonical beta-catenin signalling in retinal vascular endothelial cells, and it is the amplitude of that endothelial signal - not the identity of the component that failed - that determines the phenotype. Every conforming disorder funnels through this node, and the severity continuum across and within these diseases is a continuum in how much signal survives. Because the pathway is required both during angiogenic outgrowth and for lifelong barrier maintenance, the deficit is simultaneously developmental and ongoing.
Downstream
-
Incomplete Retinal Vascularization with Peripheral Avascular Retina
-
Inner Blood-Retina Barrier Failure
Incomplete Retinal Vascularization with Peripheral Avascular Retina
effector
The angiogenic arm. Retinal vessels normally grow centrifugally from the optic disc to the ora serrata and then dive to form the deep plexuses; without sufficient endothelial beta-catenin signal that outgrowth stalls, leaving a peripheral zone of retina permanently without a blood supply. The extent of the avascular zone is the single quantity that predicts everything downstream, which is why peripheral fluorescein angiography, not symptoms, is how family members are screened. At the severe end of the continuum the failure is not merely peripheral and the retina is dysplastic from birth.
Downstream
-
Ischaemia-Driven Neovascularization, Exudation and Tractional Detachment
Inner Blood-Retina Barrier Failure
effector
The barrier arm, separable from the angiogenic one and generally less severe. Norrin-FZD4-beta-catenin signalling stabilizes the endothelial junctional complexes that make retinal capillaries impermeable, and it does so continuously rather than only during development. Where the signal is insufficient the inner blood-retina barrier leaks, contributing exudation independently of ischaemia. This arm is partially rescued by the redundant Wnt7a/Wnt7b system, which is one reason a conformer may show a marked angiogenic phenotype with comparatively modest barrier failure.
Downstream
-
Ischaemia-Driven Neovascularization, Exudation and Tractional Detachment
Ischaemia-Driven Neovascularization, Exudation and Tractional Detachment
consequence
The avascular retina is hypoxic, and hypoxia drives VEGF-mediated neovascularization at the vascular-avascular junction. The new vessels are incompetent: they leak lipid and protein into and under the retina - the exudation the disease is named for - and the fibrovascular tissue accompanying them contracts, dragging the macula and eventually detaching the retina. This is where sight is lost in the milder end of the spectrum, and it is what laser ablation of the avascular retina and anti-VEGF therapy are aimed at. Note that it is a shared final pathway with the acquired ischaemic retinopathies and is not by itself evidence of conformance to this module.